Drug Trial Radar · NCT05659953
LMT503 First-in-human SAD, MAD, and FE Study
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Mar 1, 2027
Primary completion
Sep 1, 2027
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- Lmito Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a double-blind, randomized, placebo-controlled study, consisting of a single ascending dose (SAD) part with integrated food effect (FE) arm, and a multiple ascending dose (MAD) part to assess the safety, tolerability, and PK of ascending single and multiple oral doses of LMT503. The study will start with the SAD part.
Conditions
- Inflammatory Bowel Disease
- Colitis, Ulcerative
- Crohn Disease
Interventions
LMT503Drug
Subjects will receive one of several different oral doses of LMT503 once daily
PlaceboDrug
Subjects will receive one of several different oral doses of Placebo once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Treatment Emergent Adverse Events (TEAEs) in the SAD and MAD partTime frame: up to Day 17
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON plc Company - Early Development Services
Groningen, NZ, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.